Annexon, Inc.
Annexon, Inc. is listed today as Annexon, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2022 | $130 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Jun 2020 | $102 M | No. 2 | $50 to $250 million | equity | SEC | |
| Dec 2018 | $45 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Annexon, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2022).
SEC Form D · Jul 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2022
That is all the official record says: Annexon, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Annexon, Inc. are on record.
Investors#
20 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Bain Capital Life Sciences Investors, LLC | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Bain Capital Life Sciences Partners, LP | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BCIP Life Sciences Associates, LP | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Clarus III L.L.C. | Other | not stated | not stated | Held Series A-1, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Group Management L.L.C. | Fund or asset manager | not stated | not stated | Held Series A-1, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Holdings I/II GP Inc | Company | not stated | not stated | Held Series A-1, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Holdings II L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Blackstone Inc. | Fund or asset manager | not stated | not stated | Held Series A-1, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Clarus Lifesciences III, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Clarus Ventures III GP, L.P. | Venture capital | not stated | not stated | Held Series A-1, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt IV, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Deerfield Private Design Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Nea 15 GP, LLC | Other | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| NEA Partners 15, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| New Enterprise Associates 15, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 17 investors.
Largest shareholders today
Institutions holding Annexon, Inc. shares, as of Sep 30, 2026.
- FMR LLC$114 M—
- Redmile Group, LLC$60 M—
- BlackRock, Inc.$60 M—
- State Street Corp$40 M—
- BVF Inc/il$35 M—
- Vanguard Capital Management LLC$33 M—
- Mak Capital One LLC$33 M—
- Ameriprise Financial Inc$25 M—
- Bain Capital Life Sciences Investors, LLC$19 M—
- Siren, L.L.C.$18 M—
- MPM Bioimpact LLC$18 M—
- Geode Capital Management, LLC$18 M—
- Qube Research & Technologies Ltd$17 M—
- Goldman Sachs Group Inc$17 M—
- Woodline Partners LP$16 M—
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Douglas Love | Executive officer | Jul 2022 |
| Jennifer Lew | Executive officer | Jul 2022 |
| Larry C. Mattheakis, Ph.D | Executive officer | Jul 2022 |
| Michael C. Overdorf | Executive officer | Jul 2022 |
| Sanjay Keswani | Executive officer | Jul 2020 |
| Ted Yednock | Executive officer | Jul 2020 |
| Mark L Smith | Executive officer | Dec 2018 |
| Ted L Yednock | Executive officer | Dec 2018 |
| Bettina M. Cockroft, M.D. | Director | Jul 2022 |
| Douglas Love | Director | Jul 2022 |
| Jung E. Choi | Director | Jul 2022 |
| Muneer A. Satter | Director | Jul 2022 |
| Thomas G. Wiggans | Director | Jul 2022 |
| William D. Waddill | Director | Jul 2022 |
| William H. Carson, M.D. | Director | Jul 2022 |
| Campbell E. Murray | Director | Jul 2020 |
| Carol E. Gallagher | Director | Jul 2020 |
| Emmett E. Cunningham | Director | Jul 2020 |
| Ricky A. Sun | Director | Jul 2020 |
| William D. Young | Director | Jul 2020 |
| Campbell L Murray | Director | Dec 2018 |
| Carol L Gallagher | Director | Dec 2018 |
| Emmett L Cunningham | Director | Dec 2018 |
| Muneer L Satter | Director | Dec 2018 |
| Ricky L Sun | Director | Dec 2018 |
| Thomas L Wiggans | Director | Dec 2018 |
| William L Young | Director | Dec 2018 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.